VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

portfolio company news
Written By Brad Good
Brad Good

Brad Good has been an endorsed Squarespace Expert since the beginning and has been working on the platform since 2008. He has helped hundreds of Squarespace customers with their websites.

http://www.bradgood.net
Previous

Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701
Next

Corbus Pharmaceuticals expands oncology pipeline with the addition of a clinical stage Nectin-4 targeting Antibody Drug Conjugate (ADC)